ArticleBMC cancer2020
Multiple m
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma.Cancer cell international · 2025Review
- The role of YTHDF2 in anti-tumor immunity.Cell investigation · 2025Article
- New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma.Acta pharmacologica Sinica · 2024Review
- Clinical significance of RNA methylation in hepatocellular carcinoma.Cell communication and signaling : CCS · 2024Review
- hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.Journal of translational medicine · 2023Article
- Review
- N6-methyladenosine regulators are potential prognostic biomarkers for multiple myeloma.IUBMB life · 2023Article
- Period2 is associated with immune cell infiltration and is a potential diagnostic and prognostic marker for hepatocellular carcinoma.Frontiers in molecular biosciences · 2023Article
- Ferroptosis-related genes with post-transcriptional regulation mechanisms in hepatocellular carcinoma determined by bioinformatics and experimental validation.Annals of translational medicine · 2022Article
- NCancers · 2022Review
- Role of main RNA modifications in cancer: NSignal transduction and targeted therapy · 2022Review
- mExperimental hematology & oncology · 2022Review
- CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via mMolecular therapy oncolytics · 2022Article
- Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma.Frontiers in genetics · 2022Article
- The role of RNA modification in hepatocellular carcinoma.Frontiers in pharmacology · 2022Review
- Knockdown of METTL14 suppresses the malignant progression of non-small cell lung cancer by reducing Twist expression.Oncology letters · 2021Article
- Systematic expression analysis of mBJUI compass · 2021Article
- NCancer communications (London, England) · 2021Review
- Novel prognostic implications of YTH domain family 2 in resected hepatocellular carcinoma.Oncology letters · 2021Article
- A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.BMC cancer · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in the world. N
methodsFirst, using data from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases, we compared the expression levels of 13 major m6A RNA methylation modulators between HCC and normal tissues. Second, we applied consensus clustering to the expression data on the m
resultsWe found that the expression levels of 12 major m6A RNA methylation modulators were significantly different between HCC and normal tissues. After dividing the HCC tissues into clusters 1 and 2, we found that cluster 2 had poorer OS, higher WHO stage, and higher pathological grade. Four m
conclusionsIn summary, m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.